Search
forLearn
5 / 801 resultslearn Tripeptide-1
learn copper tripeptide-1
learn retinoic acid
learn oligopeptide-71
Research
5 / 129 resultsresearch The Effect of EGR1 on the Proliferation of Dermal Papilla Cells
Increasing EGR1 levels makes hair root cells grow faster.
research LL-37 stimulates the functions of adipose-derived stromal/stem cells via early growth response 1 and the MAPK pathway
LL-37 helps stem cells grow and move, aiding tissue regeneration and hair growth.
research P02 Accelerated ageing of hair follicles in androgenetic alopecia
Hair follicles in androgenetic alopecia age faster, especially in the front.
research Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics
Understanding and targeting specific molecules can help reduce scarring and promote scar-free healing.
research DNA Methylation Mediates lncRNA2919 Regulation of Hair Follicle Regeneration
DNA methylation controls lncRNA2919, which negatively affects hair growth.
Community Join
5 / 1000+ resultscommunity IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community MCL1 does anyone knows anthying about it
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.